secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001213900-26-029761
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex reports ~$75M cash, no debt; advances IHL-42X sleep apnea program
--------------------------------------------------------------------------

- Cash position ~$75M, no debt; market cap ~$46M, resulting in negative enterprise value.
- Financing led by healthcare-focused institutional investors funds DReAMzz dose-optimization study for IHL-42X.
- Company expects to start dosing DReAMzz study within months; Phase 2 results showed significant OSA improvements.
- PSX-001 for generalized anxiety disorder progressing with open IND and clinical advisory board.
- Board-approved share buyback program remains available for shareholder value delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026029761/0001213900-26-029761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026029761/ea0282288-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-029761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer